A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
PRIMARY OBJECTIVES:
I. To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral ductal carcinoma in situ (IIBCR-SCR-DCIS) in women with human epidermal growth factor receptor 2 (HER2)-positive DCIS resected by lumpectomy.
SECONDARY OBJECTIVES:
I. Determine the value of trastuzumab given during RT compared to RT alone in prolonging invasive or DCIS disease-free survival (IDFS)-DCIS.
II. Determine the value of trastuzumab given during RT compared to RT alone in increasing invasive or DCIS recurrence-free interval.
III. Determine the value of trastuzumab given during RT compared to RT alone in improving regional or distant recurrence.
IV. Determine the value of trastuzumab given during RT compared to RT alone in improving the incidence of contralateral invasive or DCIS breast cancer.
V. Determine the value of trastuzumab given during RT compared to RT alone in improving survival.
VI. To explore the effect of trastuzumab on ovarian function.
TERTIARY OBJECTIVES:
I. To determine if the benefit of trastuzumab added to RT will be significantly higher in v-myc avian myelocytomatosis viral oncogene homolog (cMYC)-amplified tumors than in the cMYC non-amplified subset.
II. To determine if the benefit of trastuzumab added to RT will be less in tumors with mutations in the phosphatidylinositol 3 (PI3) kinase gene than in tumors without PI3 kinase gene mutations.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo standard whole breast irradiation (WBI) over 5-6 weeks.
ARM II: Patients receive trastuzumab intravenously (IV) over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
After completion of study treatment, patients are followed up every 6 months for 5 years and then every 12 months for 5 years.
Inclusion Criteria:
Exclusion Criteria:
Invasive (including microinvasion staged as T1mic) breast cancer (patients with DCIS "suspicious" for microinvasion, but not confirmed, are eligible)
Nodal staging of pN1 (including pN1mi) (note: axillary staging is not required)
DCIS present in more than one quadrant (multicentric)
Masses or clusters of calcification that are clinically or mammographically suspicious unless biopsied and proven to be benign (if DCIS is found, the patient is eligible if the DCIS was in the same quadrant of the ipsilateral breast and was resected with clear margins)
Contralateral breast cancer (including DCIS)
Whole breast irradiation administered before randomization (partial breast irradiation is prohibited)
Prior history of breast cancer, including DCIS (patients with a history of LCIS are eligible)
Prior anthracycline chemotherapy for any malignancy
Cardiac disease that would preclude the use of the drugs included in the B-43 treatment regimens; this includes but is not confined to:
Active cardiac disease:
History of cardiac disease:
Uncontrolled hypertension, i.e., systolic blood pressure [BP] greater than 180 mm/Hg and/or diastolic BP greater than 100 mm/Hg (patients with hypertension that is well controlled on medication are eligible)
Other nonmalignant systemic disease that would preclude a patient from receiving trastuzumab or radiation therapy or would prevent prolonged follow-up
Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization and is deemed by her physician to be at low risk for recurrence; patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin
Pregnancy or lactation at the time of study entry (note: pregnancy testing according to institutional standards should be performed for women of child-bearing potential)
Administration of any investigational agent within 30 days before study entry
Burbank, California 91505, United States
Cameron Park, California 95682, United States
Roseville, California 95661, United States
San Pablo, California 94806, United States
Washington D.C., District of Columbia 20002, United States
Jacksonville, Florida 32209, United States
Chicago, Illinois 60657, United States
Highland Park, Illinois 60035, United States
Baltimore, Maryland 21237, United States
Milford, Massachusetts 01757, United States
South Weymouth, Massachusetts 02190, United States
Grand Rapids, Michigan 49503, United States
Saint Joseph, Michigan 49085, United States
Saint Joseph, Michigan 49085, United States
Saint Louis Park, Minnesota 55416, United States
Las Vegas, Nevada 89109, United States
Las Vegas, Nevada 89113, United States
Las Vegas, Nevada 89149, United States
Lebanon, New Hampshire 03756, United States
Elizabeth, New Jersey 07207, United States
East Syracuse, New York 13057, United States
Poughkeepsie, New York 12601, United States
Winston-Salem, North Carolina 27104, United States
Scranton, Pennsylvania 18508, United States
Sioux Falls, South Dakota 57117-5045, United States
Houston, Texas 77030, United States
American Fork, Utah 84003, United States
Berlin Corners, Vermont 05602, United States
Spokane, Washington 99204, United States
Spokane, Washington 99204, United States
Spokane Valley, Washington 99216, United States
Yakima, Washington 98902, United States
Johnson Creek, Wisconsin 53038, United States
Madison, Wisconsin 53792, United States
Milwaukee, Wisconsin 53210, United States
Summit, Wisconsin 53066, United States
Montreal, Quebec H3H 2R9, Canada